VIR BIOTECHNOLOGY INC. news, videos and press releases
For more news please use our advanced search feature.
VIR BIOTECHNOLOGY INC. - More news...
VIR BIOTECHNOLOGY INC. - More news...
- Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
- Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
- Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference
- Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
- Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
- Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
- Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
- Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
- Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
- Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
- Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
- Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
- Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
- Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
- Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
- Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
- Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023
- Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
- Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer
- Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
- Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023
- Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
- Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders
- Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer
- Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI
- Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
- Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference
